Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Payables (2020 - 2024)

Historic Payables for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $4.8 million.

  • Burning Rock Biotech's Payables rose 3181.82% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 3181.82%. This contributed to the annual value of $4.7 million for FY2024, which is 7338.74% up from last year.
  • Latest data reveals that Burning Rock Biotech reported Payables of $4.8 million as of Q3 2025, which was up 3181.82% from $4.6 million recorded in Q2 2025.
  • Burning Rock Biotech's Payables' 5-year high stood at $28.1 million during Q4 2021, with a 5-year trough of $933000.0 in Q2 2022.
  • In the last 5 years, Burning Rock Biotech's Payables had a median value of $4.7 million in 2024 and averaged $6.8 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Payables soared by 32743.61% in 2021, and later crashed by 8771.24% in 2022.
  • Over the past 5 years, Burning Rock Biotech's Payables (Quarter) stood at $28.1 million in 2021, then tumbled by 72.76% to $7.6 million in 2022, then tumbled by 64.53% to $2.7 million in 2023, then skyrocketed by 73.39% to $4.7 million in 2024, then increased by 2.95% to $4.8 million in 2025.
  • Its Payables was $4.8 million in Q3 2025, compared to $4.6 million in Q2 2025 and $5.0 million in Q1 2025.